Peter Heutink

Company: Alector Pharmaceuticals LLC

Job title: Chief Scientific Officer

Seminars:

Targeting the Microglia Brain Immune system with TREM2 Agonism as a Broad Therapy for Alzheimer’s Disease 5:00 pm

Trem2 is a damage sensing microglia receptor. Partial loss of TREM2 increases AD risk while high levels appear protective AL002, Alector Trem2 activating biologics was shown to be well tolerated, engage microglia and is associated with incidences of ARIA-like events in AD Clinical, imaging, and biomarkers data from a double-blind, placebo-controlled, 4-dose arm, Phase 2…Read more

day: Conference Day One

Targeting the Microglia Brain Immune system with TREM2 Agonism as a Broad Therapy for Alzheimer’s Disease 11:00 am

Trem2 is a damage sensing microglia receptor. Partial loss of TREM2 increases AD risk while high levels appear protective AL002, Alector Trem2 activating biologics was shown to be well tolerated, engage microglia and is associated with incidences of ARIA-like events in AD Clinical, imaging, and biomarkers data from a double-blind, placebo-controlled, 4-dose arm, Phase 2…Read more

day: Clinical & Commercial Track Day 2 AM

Panel Discussion: How has the Recent Approval of Disease Modifying Drugs Impacted the Treatment Landscape for Alzheimer’s Disease? 9:30 am

Exploring the potential impact on novel target discovery and development strategies Illuminating the impact on clinical development plans in demonstrating meaningful effect on patients Reviewing how trial design might be impacted with Leqembi as a comparator or combination partner in future studiesRead more

day: Conference Day Two